HLS Therapeutics Inc.
TSX:HLS.TODrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $116.32M
- Beta
- 0.85
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.33
Volume 0.04M
Average 0.01M
HLS.TO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
HLS Therapeutics Inc.TSX: HLS.TO
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 30.4% from a year ago
Cash & equivalents stood at $12.33M at the end of Q1 FY2026, down 30.4% from a year earlier and up 5.4% from the prior quarter. Over 3 fiscal years it compounded at -17.3% a year.
Context
- Cash & equivalents amounted to 9.4% of total assets at the end of Q1 FY2026, down 2.1 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -30.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 11.7M USD
- Year-over-year change
- -33.0%
- 4-year CAGR
- -13.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.7M | -33.0% |
| FY2024 | 2024-12-31 | 17.46M | -20.5% |
| FY2023 | 2023-12-31 | 21.95M | +5.9% |
| FY2022 | 2022-12-31 | 20.72M | -2.2% |
| FY2021 | 2021-12-31 | 21.18M | — |
Cash & Equivalents vs competitors
How HLS.TO compares with its peers on the latest reported figures
- HLS.TO's Mar 2026 cash & equivalents of $12.33M is the 6th highest of the 7 companies compared; the peer median is $119.19M.
- Its year-over-year change of -30.4% is the lowest of 7, against a peer median of +35.0%.
- Cash & equivalents amounts to 9.4% of total assets for HLS.TO, versus a peer median of 17.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $24.65B | +161575.2% | +31.6% | 25.9% | |
| Jun 2026 | $1.83B | +5.7% | +32.9% | 7.4% | |
| Jun 2026 | $127.64M | +57.2% | +128.7% | 3.4% | |
| Mar 2026 | $110.73M | +61.3% | +64.4% | 78.5% | |
| Mar 2026 | $19.66M | +12.9% | +16.7% | 20.1% | |
| Mar 2026 | $12.33M | -30.4% | -17.3% | 9.4% | |
| Mar 2026 | $11.01M | -27.1% | -16.6% | 15.5% | |
| Peer median (excluding HLS.TO) | $119.19M | +35.0% | +32.2% | 17.8% | |
Competitors are the stored peer set for HLS.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21.18M | 20.72M | 21.95M | 17.46M | 11.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 11.51M | 11.19M | 10.69M | 7.53M | 7.85M |
| Inventory | 8.93M | 8.9M | 9.53M | 9.06M | 8.12M |
| Other Current Assets | 1.74M | 1.43M | 2K | 1 | 1.37M |
| Total Current Assets | 43.75M | 44.37M | 44.1M | 35.4M | 29.04M |
| Property, Plant & Equipment (Net) | 1.57M | 1.13M | 965K | 997K | 1.34M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 229.18M | 195.02M | 162.34M | 122.12M | 105.43M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 690K | 465K | 1.04M | 857K | 1.14M |
| Other Non-current Assets | 714K | 668K | 1.66M | 528K | 327.41K |
| Total Non-current Assets | 232.15M | 197.28M | 164.97M | 124.5M | 108.24M |
| Total Assets | 275.91M | 241.65M | 209.06M | 159.9M | 137.28M |
| Account Payables | 9.32M | 11.59M | 14.11M | 8.71M | 10.42M |
| Short-term Debt | 12M | 13.06M | 4.69M | 4.83M | 4.33M |
| Tax Payables | 97K | 0 | 281K | 152K | 0 |
| Deferred Revenue | 4.85M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 901K | 6.02M | 7.14M | 8.4M | 10.43M |
| Total Current Liabilities | 27.67M | 31.19M | 26.69M | 22.55M | 26.07M |
| Long-term Debt | 84.13M | 83.28M | 82.05M | 60.74M | 44.37M |
| Deferred Tax Liabilities | 653K | 566K | 442K | 4.07M | 3.05M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.54M | 817K | 1.77M | 778K | 1.67M |
| Total Non-current Liabilities | 87.5M | 85.14M | 84.68M | 66.02M | 49.65M |
| Total Liabilities | 115.17M | 116.33M | 111.36M | 88.56M | 75.72M |
| Common Stock | 265.92M | 265.21M | 262.13M | 260.6M | 255.87M |
| Retained Earnings | (119.86M) | (148.45M) | (175.46M) | (194.18M) | (203.78M) |
| Accumulated OCI | 2.96M | (5.26M) | (2.84M) | (10.21M) | (6.67M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 160.74M | 125.32M | 97.7M | 71.34M | 61.56M |
| Total Debt | 97.57M | 97.35M | 87.62M | 66.45M | 49.73M |
| Net Debt | 76.39M | 76.62M | 65.67M | 48.99M | 38.03M |
HLS Therapeutics Inc.
TSX:HLS.TO
Intrinsic Alpha fair value
Locked
Current Price
$3.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.